Peer-influenced content. Sources you trust. No registration required. This is HCN.


Cancer Therapy Advisor

Discontinuation of Bevacizumab in Ovarian Cancer May Result in Rebound

Obstetrics & Gynecology August 14th 2023

NEJM Evidence

My Experience in a Clinical Trial for a Rare Gynecologic Cancer

Obstetrics & Gynecology August 1st 2023

OBR Oncology

“Unprecedented” PFS Benefit with Selinexor in p53 Wild-Type Endometrial Cancer

Obstetrics & Gynecology August 1st 2023

Oncology Learning Network

Efficacy and Safety of Chemoradiation for Patients with Stage IB3 Cervical Cancer

Obstetrics & Gynecology May 8th 2023

Roswell Park

Personalized Medicine in Gynecologic Oncology

Oncology, Medical November 28th 2022

Cancer Therapy Advisor

Cancer Treatment Regimens

Hematology/Oncology October 7th 2022

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form